Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 2, Février 2015
Page(s) 132 - 134
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20153102006
Publié en ligne 4 mars 2015
  1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropath 1991 ; 82 : 239–259. [CrossRef] [PubMed]
  2. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998 ; 393 : 702–705. [CrossRef] [PubMed]
  3. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992 ; 42 : 631–639. [CrossRef] [PubMed]
  4. Zhou J, Gennatas ED, Kramer JH, et al. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 2012 ; 73 : 1216–1227. [CrossRef] [PubMed]
  5. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 2010 ; 11 : 55–59.
  6. Augustinack JC, Schneider A, Mandelkow E-M, Hymen BT. Specific Tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol 2002 ; 103 : 26–35. [CrossRef] [PubMed]
  7. Deters N, Ittner LM, Gotz J. Divergent phosphorylation pattern of Tau in P301L tau transgenic mice. Eur J Neurosci 2008 ; 28 : 137–147. [CrossRef] [PubMed]
  8. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies. Nat Rev Drug Discov 2009 ; 8 : 783–793. [CrossRef] [PubMed]
  9. Pooler AM, Phillips EC, Lau DH, et al. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 2013 ; 14 : 389–394. [CrossRef] [PubMed]
  10. Lee VM, Brunden KR, Hutton M, Trojanowski JQ. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. CSH Perspect Med 2011 ; 1 : a006437.
  11. Noack M, Leyk J, Richter-Landsberg C. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes. Glia 2014 ; 62 : 535–547. [CrossRef] [PubMed]
  12. Wang YP, Biernat J, Pickhardt M, et al. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci USA 2007 ; 104 : 10252–10257. [CrossRef]
  13. Bulic B, Pickhardt M, Mandelkow E. Progress and developments in tau aggregation inhibitors for Alzheimer disease. J Med Chem 2013 ; 56 : 4135–4155. [CrossRef] [PubMed]
  14. Yanamandra K, Kfoury N, Mahan TE, et al. Anti-Tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013 ; 80 : 402–414. [CrossRef] [PubMed]
  15. Asuni AA, Boutajangout A, Quatermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007 ; 27 : 9115–9129. [CrossRef] [PubMed]
  16. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011 ; 118 : 658–667. [CrossRef] [PubMed]
  17. Troquier L, Cailleriez R, Burnouf S, et al. Targeting phosphor-Ser422 by active Tau immunotherapy in the THYTau22 mouse model : a suitable therapeutic approach. Curr Alzheimer Res 2012 ; 9 : 397–405. [CrossRef] [PubMed]
  18. Rozenstein-Tsalovich L, Grigoriadis N, Lourbopoulos A, et al. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 2013 ; 248 : 451–456. [CrossRef] [PubMed]
  19. Grueninger F, Bohrmann B, Czech C, et al. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol Dis 2010 ; 37 : 294–306. [CrossRef] [PubMed]
  20. Collin L, Bohrmann B, Göpfert U, et al. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease. Brain 2014 ; 137 : 2834–2846. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.